Point72 Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Point72 Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$851K	Buy	+4,500	New	+$786K	﹤0.01%	2857
2025 Q2	–	Sell	-40,000	Closed	-$4.97M	–	2410
2025 Q1	$4.97M	Buy	+40,000	New	+$5.22M	0.01%	931
2024 Q2	–	Sell	-6,900	Closed	-$831K	–	2147
2024 Q1	$831K	Sell	6,900 -5,000	-42%	-$612K	﹤0.01%	1509
2023 Q4	$1.46M	Sell	11,900 -4,000	-25%	-$499K	﹤0.01%	1298
2023 Q3	$2.06M	Buy	+15,900	New	+$2.12M	0.01%	1128
2019 Q2	–	Sell	-15,800	Closed	-$2.26M	–	1433
2019 Q1	$2.26M	Buy	+15,800	New	+$2.06M	0.01%	687

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management's JAZZ Position: Q1 2026 in Review

Point72 Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 105% in Q1 2026, buying an estimated $32.1M and bringing the position to 358,634 shares worth $67.8M. The position accounts for 0.09% of the portfolio, ranked #271.

Point72 Asset Management first reported a position in JAZZ in Q3 2015 and has held it in 29 quarters since. The position peaked at $123M in Q4 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Point72 Asset Management held 358,634 shares of Jazz Pharmaceuticals worth $67.8M as of Q1 2026.
Point72 Asset Management bought 183,634 Jazz Pharmaceuticals shares in Q1 2026, an estimated $32.1M.
Jazz Pharmaceuticals made up 0.09% of Point72 Asset Management's portfolio in Q1 2026, its #271 holding.
Point72 Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2015 and has held it in 29 quarters since.
Point72 Asset Management's Jazz Pharmaceuticals position peaked at $123M in Q4 2021.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.